<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03402503</url>
  </required_header>
  <id_info>
    <org_study_id>IGX-CLI-2017-001</org_study_id>
    <nct_id>NCT03402503</nct_id>
  </id_info>
  <brief_title>Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IntelGenx Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IntelGenx Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety, feasibility, tolerability and efficacy of a
      new buccal film of montelukast in patients with mild to moderate Alzheimer's disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 19, 2018</start_date>
  <completion_date type="Anticipated">October 19, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Neuropsychological test battery (NTB) Composite</measure>
    <time_frame>26 weeks</time_frame>
    <description>Evaluate if treatment with one strength of montelukast new buccal film administered once a day is superior to placebo, assessed at Week 26 using the global NTB composite score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global NTB Composite</measure>
    <time_frame>26 weeks</time_frame>
    <description>Evaluate whether treatment with montelukast administered once a day is superior to placebo, assessed using the global NTB composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini Mental State Examination (MMSE)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Evaluate whether 26 weeks of treatment with montelukast improved scores using the MMSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Evaluate whether 26 weeks of treatment with montelukast improved scores using the ADCS-CGIC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living, 23-items scale (ADCS-ADL23)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Evaluate whether 26 weeks of treatment with montelukast improved scores using the ADCS-ADL23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory</measure>
    <time_frame>26 weeks</time_frame>
    <description>Evaluate whether 26 weeks of treatment with montelukast improved the behavioral disturbance in patients, measured by the neuropsychiatric inventory (NPI), compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Suicide Tracking Scale (S-STS)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Evaluate whether 26 weeks of treatment with montelukast affected suicidal risk, measured by the S-STS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinency Frequency Rating</measure>
    <time_frame>26 weeks</time_frame>
    <description>Evaluate whether 26 weeks of treatment with montelukast improved bladder incontinence in patients who reported this problem, measured by recording events and observations in the incontinency frequency rating.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>montelukast buccal film</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo buccal film</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast new buccal film</intervention_name>
    <description>montelukast buccal film once daily.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo buccal film</intervention_name>
    <description>Placebo buccal film once daily</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate Alzheimer's Disease.

          -  MMSE score of 14 - 22

          -  CT or MRI within 18 months prior to screening indicating clinical phenotype of
             Alzheimer's Disease

          -  Treated daily with donepezil, rivastigmine or galantamine for â‰¥ 3 months

          -  All other medications for chronic conditions should have been at a stable dose for at
             least 2 weeks prior to first dose. F

          -  No clinically meaningful abnormalities on electrocardiogram (ECG), physical
             examination and clinical laboratory tests

        Exclusion Criteria:

          -  Taken memantine within 2 months prior to screening.

          -  Current diagnosis of any psychiatric disorder, depression that is not well-controlled,
             clinically significant or unstable systemic disease, or severe medical procedures

          -  Clinically relevant abnormal laboratory values suggesting an unknown disease and
             requiring further clinical evaluation.

          -  Patients at imminent risk of self-harm, based on clinical interview and response on
             S-STS

          -  History of malignancy occurring within 5 years immediately prior to screening, except
             for a subject who has been adequately treated for (1) basal cell or squamous cell skin
             cancer, (2) in situ cervical cancer, (3) localized prostate carcinoma, or (4) who has
             undergone potentially curative therapy with no evidence of recurrence for more than 3
             years post-therapy, and who is deemed at low risk for recurrence by her/his treating
             physician

          -  History of any of the following cardiovascular conditions that an unstable:

               -  Hypotension

               -  Hypertension

               -  Active cardiovascular disease

          -  Evidence of cerebrovascular disease

               -  Daily antipsychotic or anxiolytic use (eg, lorazepam can be used as rescue
                  anxiolytic as long as not used within 24 hours of a clinic visit);

               -  Low potency antipsychotic agents (eg chlorpromazine) - not permitted at any time
                  during the study;

               -  Anti-parkinson's disease medications (selegiline, levodopa, amantadine) for the
                  treatment of Parkinson's Syndrome Complex;

               -  Lithium;

               -  Clozapine;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

